
Tenet Healthcare (THC) Stock Forecast & Price Target
Tenet Healthcare (THC) Analyst Ratings
Bulls say
Tenet Healthcare demonstrated robust financial performance in the third quarter, with consolidated net operating revenue reaching $5.3 billion and a 12% year-over-year increase in adjusted EBITDA to $1.1 billion, reflecting a solid margin of 20.8%. The company's Hospital segment showed positive trends, highlighted by a 1.4% growth in adjusted admissions and a 5.9% rise in revenue per adjusted admission, driven by a favorable payor mix and higher-acuity cases, leading to improved margins. Management's raised revenue guidance for the year and anticipated growth in both hospital and ambulatory surgery center segments further underpin a positive outlook on Tenet Healthcare’s stock.
Bears say
Tenet Healthcare is facing a negative outlook primarily due to its underperformance in EBITDA growth compared to peers, with a modest $50 million raise in Q3 2025 that falls short of expectations and industry benchmarks. Furthermore, the company’s leverage indicates a risky balance sheet, compounded by significant exposure to government-sponsored reimbursement programs and geographic concentration risks. Additionally, potential adverse shifts in payer mix could lead to increased volatility in operating trends, further exacerbating the company's financial challenges.
This aggregate rating is based on analysts' research of Tenet Healthcare and is not a guaranteed prediction by Public.com or investment advice.
Tenet Healthcare (THC) Analyst Forecast & Price Prediction
Start investing in Tenet Healthcare (THC)
Order type
Buy in
Order amount
Est. shares
0 shares